Clinical Trials Logo
  1. Home
  2. Schizophrenic Disorders
  3. NCT00600756

Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone — RECOVER  

Schizophrenic Disorders Clinical Trial

Official title:
A One-Year Randomized, Prospective, Parallel, Open Comparison of Subjective Well-being in Schizophrenic Out-patients Treated With Quetiapine XR (SEROQUEL XR™) or Oral Risperidone at Flexible Dose in a Naturalistic Setting

Clinical Trial Summary

The trial is designed to assess the long term subjective well-being in schizophrenic outpatients treated with quetiapine XR (extended release) or oral risperidone at flexible dose in a naturalistic setting over a period of one year. Secondary outcome measures have been selected for helping in the differentiation of the compared atypical antipsychotics. The primary objective of this study is to demonstrate the non-inferiority of quetiapine XR to risperidone assessed at month 6 in terms of responder rate using the self-report instrument SWN-K

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00600756
Study type Interventional
Source AstraZeneca
Contact
Status Completed
Phase Phase 3
Start date January 2008
Completion date October 2009
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04608032 - Neuropsychological Assessment of Remediation for Cognitive Impairments in Schizophrenia N/A
Terminated NCT00660595 - Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose Phase 3
Completed NCT02655172 - Have a Good Grasp of the Worldthe World N/A
Completed NCT01606436 - A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia Phase 1
Completed NCT01729650 - Effectiveness of a Physical Activity and Diet Program in Patients With Psychotic Disorder (CapiCor) N/A
Completed NCT00488319 - Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia. Phase 3
Completed NCT02525315 - Interest of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Auditory Hallucinations Phase 2
Completed NCT00088491 - Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia Phase 3
Completed NCT01279213 - Clozapine/Paliperidone Versus Clozapine/Placebo in Resistant Schizophrenia Phase 4
Completed NCT00572247 - The Psychiatric Rehabilitation Approach to Weight Loss N/A
Completed NCT00491569 - Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia Phase 2
Completed NCT00328276 - Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia Phase 2
Completed NCT00485823 - Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia Phase 4
Active, not recruiting NCT00161408 - Psychological Intervention for Relapse Prevention in First Episode Schizophrenia N/A
Terminated NCT05164289 - Interest of EMDR Schizophrenic Disorders
Withdrawn NCT00276263 - Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia Phase 2
Completed NCT00088465 - Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder Phase 3
Withdrawn NCT02654405 - Sodium Butyrate For Improving Cognitive Function In Schizophrenia Phase 2/Phase 3
Completed NCT02544516 - Upside Down, Give me the Handle N/A
Completed NCT00960219 - D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia Phase 2